Clinical Trials
11 trialsNCT04888741 2026-05-05
MoTD
University of Birmingham
Phase 2 Recruiting
NCT03852407 2022-10-12
HLA
University of Liege
Phase 2 Recruiting
NCT00709592 2018-11-09
Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT
Virginia Commonwealth University
Phase 2 Completed
NCT01246206 2018-06-18
Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT00617929 2017-12-28
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00899847 2017-10-20
Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG
Stanford University
Phase 2 Completed
NCT00691015 2017-06-28
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT01534143 2017-04-05
High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant
Barbara Ann Karmanos Cancer Institute
Phase 2 Terminated
NCT00133367 2016-07-25
Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus
Massachusetts General Hospital
Phase 2 Completed
NCT00720629 2014-07-18
Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00787761 2012-10-01
Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer
Northside Hospital, Inc.
Phase 2 Completed